InvestorsHub Logo
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

Re: bladerunner1717 post# 1335

Saturday, 05/30/2020 8:13:12 PM

Saturday, May 30, 2020 8:13:12 PM

Post# of 1396
SunTrust's analysis of MEIP

MEI Pharma initiated with a Buy at SunTrust SunTrust analyst Robyn Karnauskas initiated coverage of MEI Pharma with a Buy rating and $16 price target, saying the company has demonstrated strong risk-benefit profile in Phase 1 lymphoma trials and offers potential for accelerated approval in 3L FL. In addition to offering a potentially differentiated PI3K-delta inhibitor, the analyst believes that investors should consider a "base case $500M" peak-adjusted opportunity with potential upside from an over $3B opportunity across B-cell malignancies, along with MEI Pharma's pipeline beyond PI3K and its strong balance sheet.

Read more at:
https://thefly.com/landingPageNews.php?id=3101855


Bladerunner
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MEIP News